Rethinking biomaterials for the advancement of regenerative research & medicine
HealthX20 is a pioneering biotech company transforming the global biomaterials landscape by making research-grade materials more accessible, affordable, and abundant. By addressing critical bottlenecks in the supply of high-quality biomaterials, we empower scientists, clinicians, and innovators to accelerate discovery, improve experimental reproducibility, and translate breakthroughs into real-world medical solutions.
THE POWER OF X20
X20 Thinking questions fundamental assumptions, existing constraints, and business models entirely.
X20 Requires rethinking the entire system: markets, partners, platforms, technologies, and customer behaviours.
X20 Thinking demands nonlinear approaches, such as leapfrogging technologies, business model pivots, or radical cost restructuring.
X20 Thinking accelerates positive global health outcomes.
Why the global biomaterials ecosystem needs a major rethink
The biomaterials manufacturing ecosystem is broken. Life-changing medical treatments rely on biomaterials, but prices are excessive, access is limited, and a handful of global players control the supply. Innovation is stifled, and patients pay the price.
Imagine if you could make the cost of research-grade biomaterials more affordable; research institutes would experience a renaissance of life-saving breakthroughs.
HEALTHX20 SOLUTION
HX20 will disrupt the biomaterials industry by accelerating R&D, streamlining raw material sourcing, and scaling the production of regenerative ingredients like Native collagen and Hydroxyapatite. By providing faster, sustainably sourced, and more affordable raw materials, Healthx20 will unlock access for researchers and manufacturers, turbocharging medical breakthroughs, advancing regenerative health, and ultimately saving lives across both developed and underserved markets.
What Makes Us Different
At HealthX20, innovation is not a buzzword; it’s our blueprint. We operate at the intersection of Precision Science and proprietary HX20 Technology to deliver truly differentiated biomaterials.
Precision: Provenir
We call it Precision Harvesting. A science-led approach to biomaterial development that prioritises:
100% Traceability from source to application
High-purity extractions that preserve native biofunctionality
Selective use of biological components for maximum therapeutic value
Tailored specifications to meet research, pharmaceutical or cosmetic-grade needs
Ethical sourcing and sustainability at every step
Our precision ensures your product is built on a foundation of integrity and performance.
To ensure this, we have a single source partner to ensure 100% control over raw material
HX20 Tech: Pioneering Sustainable Technologies
Our proprietary HX20 Platform is engineered to upcycle animal by-products into advanced, high-performance biomaterials, responsibly and at scale.
Low-energy thermochemical processes
Natural structure preservation for enhanced biocompatibility
Minimal environmental impact
Modular processing is adaptable to different raw materials
Ready for formulation across food, health, medtech, and personal care sectors
HX20 Technology transforms undervalued streams into life-changing materials.
Multiple species, Multiple products
“In regenerative health, only the rich can afford it when it’s the poor that really need it.”
— Anthony Bertini
Founder, HX20
“If we can make biomaterials more accessible and affordable, we unlock a future where healing isn’t a luxury — it’s a right. Because the power to regenerate tissue, repair bones, or restore function shouldn’t belong to a few — it should belong to everyone.”
— Akshat Talwalkar
Chief Scientist, HX20
"A key advancement in biomaterials science lies in increasing accessibility to high-quality materials. By ensuring equitable access to the building blocks of life-saving research, we can foster innovation and enable more efficient clinical translation."
— Maria Taborda
Senior Scientist, HX20
OUR TEAM
-
FOUNDER & CHAIRMAN
Anthony is the Founder CEO and Chair of Organic Technology Holdings. As an investor and entrepreneur over the past 35 years in new technologies that have the potential to have a global impact, Anthony bought a fledgling technology in 2012 and formed OTH. The technology was originally designed to work with fish waste. Quickly realizing its potential, he surrounded himself with a respected group of scientists and like-minded investors and individuals to improve and apply a series of technology improvement to treat a variety of organic waste raw materials to create valuable and in demand end products throughout the world to be used in the human food and animal feed, nutraceutical, pharmaceutical and medical research and medical device industries.
-
SENIOR RESEARCH SCIENTIST & LEAD, PHD.
Maria Isabel Taborda Mejia is a Ph.D. in Biotechnology and a Biomedical Engineer with a strong passion for Industrial Biotechnology, technology development, and business innovation within the circular economy. She specializes in the development of sustainable biomaterials, with a focus on natural Hydroxyapatite (HAp) and Chitin derived from animal by-products. Her work bridges scientific research and industrial application, transforming biological waste into high-value products for use in medical, cosmetic, and agricultural industries. Currently, she contributes her expertise at Organic Technology Holdings, where she leads and supports key R&D initiatives. When she’s not in the lab or working on the next breakthrough, you’ll likely find her chasing sunshine on her bike, tackling a bouldering wall, or going for a refreshing run. Adventure and movement are her favorite ways to recharge
-
CHIEF SCIENTIST
Akshat Talwalkar has a highly accomplished and uniquely diverse techno-commercial profile that includes a PhD in microbiology, 10 publications in reputed scientific journals, six commercially successful patents in grain enzyme production along with extensive on-field commercial experience of new business and market development, technical sales, process development, strategic planning and key account management across Australia and the Asia Pacific region. Akshat's industrial experience includes substantial hands-on involvement with technology start-ups and large manufacturers where he led the conceptualization and development of new technologies, set up enzyme application labs and pilot plants, worked closely with both production managers and operators to successfully scale up scientifically intricate technologies from lab to production levels and worked closely with key stakeholders of large global clients to effectively transfer the developed technologies, offering continual on-site support until they were successfully integrated and established in customers production processes.
-
CFO
Franco Giugni is a finance professional with a chartered accounting background in taxation and extensive hands-on corporate experience across a broad range of industry sectors, focused on implementing aggressive growth strategies. Franco also leads a specialist corporate advisory firm supporting larger SMEs and small-cap ASX-listed companies with mid-market M&A requirements, as well as providing investment banking services under AFSL. Within our business, Franco plays a key role in closely overseeing the Group’s rapidly expanding local and international operations.
-
CHIEF COMMERCIAL OFFICER
Simon Adriatico is a sales, marketing and brand professional with extensive experience across the APAC region specialising in brand development, cross border commerce and ingredient commodities trading. Having run a handful of brand and marketing agencies focussed in emerging markets, Simon has worked with several of the world’s top companies including LVMH, Volkswagen Group, IOC, Bacardi and Adidas. An early pioneer of cross border e-commerce, Simon has also developed several food & beverage and health & wellness brands in Asia and Australia. Simon is an innovator and strategic thinker with a global network encompassing a diverse range of industry sectors.
Medical Advisory
-
Professor Meredith qualified as a dentist at Guys hospital in 1982 completing an MSc in Conservative Dentistry at the Eastman Dental Institute in London in 1988 and his first PhD at Imperial College in 1992. In 1993 he became a specialist in both Prosthodontics and Restorative dentistry.
His research interests have focused in Biomaterials and Biomechanics. In 1992 he invented the use of Resonance Frequency Analysis to measure dental implant stability, a technique that has now become the international benchmark known as Osstell.
He was awarded his second PhD from the University of Gothenburg for this work in 1996. Neil became Professor of Restorative Dentistry and Biomaterials at the University of Leeds in 1997.
Following his entrepeneurial spirit he invented a dental implant system with patented biomechanics and surface technology. He raised venture capital funding and founded Neoss, of which he was CEO from 2000-2011. Neoss was in the Techtrack 100 for the fasted growing UK technology companies for three years running.
2011 saw a return to academia when Neil joined the University of Queensland as Professor of Dental Implantology and Prosthodontics becoming the Head of Dentistry at James Cook University, Cairns, Australia in 2015. In 2020 Neil left his university ties to form the Postgraduate Institute of Dental Surgery which focusses on accredited diploma and certificate programs of excellence in dental implantology. He lectures internationally and is engaged in translational research and technology development.
-
I have been a dentist for nearly 50 years. I was one of a small percentage of female dentists at the time. In 1978 Dr Leonard Linkow, a pioneer in dental implants, offered me a place to do a clinical residency in his clinic in New York I spent 6 months in New York studying with him in 1978. Later I was able to study under the late Dr Carl Misch, founder of the Misch International Implant Institute in USA and one of the foremost research scientists in Dental Implants, at the time. In the 1990’s I went to Portugal to do a clinical residency under Dr Palo Malo the inventor of the All-on-4 restoration for full mouth reconstruction with implants and fixed bridges. I have recently completed a Diploma of Implant Dentistry under Professor Neil Meredith, in Australia.
These 4 men, in my opinion, are giants in the field of Dental Implants, and I have been able to use their experience, research and inventive brains to help my patients reach their goals. I have been placing implants and the related bone grafting for the past 40 years. I have also been assessing insurance claims as a medico-legal expert for over 20 years.
Products & Services
Medical & Research Grade Collagen
High-purity collagen designed for advanced medical and scientific applications. Used in wound healing, tissue engineering, and cell culture, it supports cellular regeneration and biomaterial development.
Hydroxyapatite for Dental Implants & Bone Regeneration
Bioactive calcium phosphate that mimics natural bone mineral. Ideal for dental implants and bone grafting, it promotes osseointegration and accelerates bone regeneration.
Hyaluronic Acid
A naturally occurring molecule known for its exceptional hydration and healing properties. Widely used in joint therapies, dermal fillers, and tissue scaffolds to enhance cell migration and repair.
Blood Fractionation
A process that separates whole blood into its core components — plasma, platelets, and proteins; for use in targeted therapies, diagnostics, and regenerative treatments like PRP (platelet-rich plasma).
Customisation
Got a biomaterial ingredient you need made faster, cheaper — but don’t know how? We don’t either. Yet. But we’ll figure it out with you.
We specialise in custom biomaterial development for medical, nutritional, and industrial use. With HX20’s tech and deep bio-system knowledge, we co-develop ingredients tailored to your needs — bioactivity, solubility, molecular weight, and more.
From wound care to packaging, we turn by-products into smart, scalable biomaterials.